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Total body fat content, as measured by dual X-ray absorptiometry (DXA), is highly correlated with multiple metabolic risk factors \[[@CR1]\]. Intra-abdominal (visceral) adipose tissue (VAT) also influences cardiometabolic risk factors independent of total body fat and is a major risk factor for many of the cardiometabolic complications of obesity \[[@CR2]--[@CR6]\]. Although various adipose depots can be accurately measured using dedicated imaging techniques, implementation of these modalities remain limited in clinical practice due to high cost, radiation exposure, and prolonged scan time. Multiple surrogate indices of total and visceral adiposity have been developed that do not require advanced imaging, have been validated with metabolic outcomes, and are more readily applied in the clinical setting \[[@CR7]--[@CR9]\]. Furthermore, the individual parameters used to derive these indices can be applied across a broad spectrum of populations.

Empagliflozin (EMPA) is a potent and selective sodium glucose cotransporter 2 inhibitor \[[@CR10]\]. In a Phase III, randomized, double-blind trial (EMPA-REG H2H SU™, ClinicalTrials.gov NCT01167881) in 1549 patients with type 2 diabetes (T2D), EMPA 25 mg daily as add-on to metformin for 104 weeks led to sustained reductions in Glycosylated hemoglobin (HbA1c), body weight \[MMRM-adjusted mean change from baseline −4.6 (95% CI −5.0, −4.2) kg, *P* \< 0.0001\], and blood pressure compared with glimepiride 1--4 mg \[[@CR11]\]. In an embedded, dedicated body composition sub-study, reductions in trunk fat, limb fat, total fat mass, VAT \[adjusted mean change from baseline −22.2 (95% CI −37.1, −7.4) cm^3^, *P* = 0.004\], and abdominal subcutaneous adipose tissue \[SAT; adjusted mean change from baseline −40.0 (95% CI −58.9, −21.1) cm^3^, *P* \< 0.0001\] were demonstrated with EMPA compared with glimepiride \[[@CR11]\]. EMPA has also been shown to reduce body weight and surrogate indices of total and visceral adiposity at 12 and 24 weeks among 3300 patients with T2D enrolled in five clinical trials \[[@CR12]\].

Data comparing adipose distribution indices with gold standard body composition measurements within the context of an extensively phenotyped clinical trial population with highly standardized assessments are lacking. We aimed to explore the relationships between adipose distribution indices and direct imaging assessments of body composition using baseline data from the EMPA-REG H2H SU trial.
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The EMPA-REG H2H SU trial was a double-blind, randomized, active-control trial of EMPA 25 mg daily vs. glimepiride 1--4 mg daily as add-on to metformin among adults with T2D and HbA1c concentrations of 7--10% for 104 weeks. All patients at sites choosing to contribute to a dedicated body composition sub-study were offered participation and signed separate informed consent forms. Whole body DXA and regional magnetic resonance imaging (MRI) scans (involving one axial slice from T1 sequence with and without fat suppression at the level of L4--L5 intervertebral disc) were performed \[[@CR11]\]. Scans were obtained in a standardized manner and assessed by an independent reviewer. Using Spearman's rank correlation coefficients, we assessed the correlations between gold standard body composition assessments---total fat mass and fat-free mass based on DXA and abdominal VAT and SAT based on MRI---and indices of total and visceral adiposity at baseline. Indices assessed included waist circumference (WC, cm); estimated total body fat \[eTBF; Young man's Christian association (YMCA) formula\] \[[@CR13], [@CR14]\]: 100 × (−98.42 + \[4.15 × WC (in)\]−\[0.082 × weight (lbs.)\])/weight for men and 100 × (−76.76 + \[4.15 × WC\]−\[0.082 × weight\])/weight for women; index of central obesity (ICO): WC/height \[[@CR9]\]; and visceral adiposity index (VAI) \[[@CR15]\]: (WC (cm)/\[39.68 + (1.88 × BMI)\]) × (TG/1.03) × (1.31/HDL-C) for men; (WC/\[36.58 + (1.89 × BMI)\]) × (TG/0.81) × (1.52/HDL-C) for women, where BMI is body mass index (kg/m^2^), TG is triglycerides (mmol/L) and HDL-cholesterol is high-density lipoprotein cholesterol (mmol/L). Correlations (positive or negative) were classified as negligible if 0.0--0.3, mild if 0.3--0.5, moderate if 0.5--0.7, and high if 0.7--0.9 \[[@CR16]\]. For all statistical testing, a 2-sided *P* value \<0.05 was considered statistically significant. All statistical analyses were performed using SAS version 9.2 software (SAS Corporation, Cary, NC).

Compliance with Ethics Guidelines {#Sec3}
---------------------------------

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all the patients for being included in the study.

Results {#Sec4}
=======

Baseline characteristics of 118 patients with a baseline DXA (*n* = 93) or MRI (*n* = 99) scan are shown in Table [1](#Tab1){ref-type="table"}. Patients with a baseline scan had a mean age of 55.6 years and were predominantly female and white. Body weight, WC, eTBF, ICO, and VAI were similar between DXA and MRI scanned groups.Table 1Baseline characteristics of the study population with a baseline DXA or MRI scanBaseline characteristicsPatients with a DXA scan (*n* = 93)Patients with an MRI scan (*n* = 99)Age (years)55.6 (10.8)55.6 (10.1)Male (%)39 (41.9)46 (46.5)Race (%) White74 (79.6)81 (81.8) Asian17 (18.3)14 (14.1) Black2 (2.2)4 (4.0)Time since T2D diagnosis (years) ≤112 (12.9)9 (9.1) \>1--535 (37.6)45 (45.5) \>5--1027 (29.0)23 (23.2) \>1019 (20.4)22 (22.2)HbA1c (%)8.19 (1.02)8.20 (0.99)Fasting glucose (mg/dL)159.3 (45.9)161.7 (47.2)Triglycerides (mg/dL)183.0 (116.1)^a^216.3 (259.6)^d^HDL cholesterol (mg/dL)46.4 (10.6)^a^45.2 (10.6)^d^LDL cholesterol (mg/dL)96.0 (31.3)^a^97.4 (32.0)^e^Total cholesterol (mg/dL)177.8 (38.9)^a^181.5 (43.7)^d^AST (U/L)26.7 (19.4)^a^26.6 (17.8)^d^ALT (U/L)34.1 (25.6)^a^34.9 (25.4)^d^Body weight (kg)84.1 (15.2)87.4 (16.3)Body mass index (kg/m^2^)31.9 (4.9)32.4 (4.9)Waist circumference (cm)103.9 (12.1)106.1 (12.3)Est total body fat (%)37.4 (9.9)37.1 (9.6)Index of central obesity0.64 (0.08)0.65 (0.08)Visceral adiposity index3.3 (3.1)^a^4.4 (8.5)^d^Total fat mass (%)38.4 (8.4)38.9 (8.0)^b^Fat-free mass (kg)50.8 (10.7)50.7 (11.2)^b^Visceral fat mass (cm^2^)164.1 (81.3)^b^174.0 (80.7)Abdominal subcutaneous fat mass (cm^2^)338.4 (107.6)^c^342.2 (111.4)Data are mean (standard deviation) or *n* (%).*DXA* dual x-ray absorptiometry, *MRI* magnetic resonance imaging, *T2D* Type 2 diabetes, *HbA1c* glycosylated hemoglobin, *HDL* high-density lipoprotein, *LDL* low-density lipoprotein, *AST* Aspartate transaminase, *ALT* Alanine transaminaseSubjects with data available: ^a^ *n* = 92; ^b^ *n* = 74; ^c^ *n* = 73; ^d^ *n* = 98; ^e^ *n* = 97

WC was mildly correlated with percent total body fat (Spearman's *ρ* = 0.31, *P* = 0.002) and fat-free mass (Spearman's *ρ* = 0.44, *P* \< 0.001) but moderately correlated with VAT (Spearman's *ρ* = 0.66, *P* \< 0.001, Fig. [1](#Fig1){ref-type="fig"}a) and SAT (Spearman's *ρ* = 0.55, *P* \< 0.001). eTBF was highly correlated with total body fat (Spearman's *ρ* = 0.73, *P* \< 0.001, Fig. [1](#Fig1){ref-type="fig"}b) and moderately correlated with SAT (Spearman's *ρ* = 0.51, *P* \< 0.001), but not significantly associated with VAT. ICO was moderately correlated with total body fat (Spearman's *ρ* = 0.61, *P* \< 0.001), VAT (Spearman's *ρ* = 0.52, *P* \< 0.001, Fig. [1](#Fig1){ref-type="fig"}c), and SAT (Spearman's *ρ* = 0.67, *P* \< 0.001), but not with fat-free mass. VAI was negligibly correlated with VAT (Spearman's *ρ* = 0.24, *P* = 0.02, Fig. [1](#Fig1){ref-type="fig"}d) and was not significantly associated with SAT.Fig. 1Correlations between **a** waist circumference and VAT; **b** estimated total body fat and total fat mass by DXA; **c** index of central obesity and VAT; and **d** visceral adiposity index and VAT. *DXA* dual x-ray absorptiometry, *VAT* visceral adipose tissue
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In this post hoc analysis using a subset of the 1549 patients with T2D randomized to treatment with EMPA vs. glimepiride in the EMPA-REG H2H SU trial with baseline DXA or MRI, we found that eTBF (using sex-specific equations incorporating weight and WC) was highly representative of total body fat mass by DXA, but not associated with visceral adiposity by MRI. By contrast, WC and ICO had the strongest relation to regional abdominal adiposity with VAT and SAT. Surprisingly, VAI was not highly correlated with MRI-based assessment of VAT. These findings support the use of eTBF for non-imaging estimations of total body fat and the use of WC or ICO as surrogate indices for abdominal VAT and SAT for both clinical and research purposes in the absence of gold standard methodology.

The eTBF index used in this study derives from the popularly termed YMCA formula, referencing the community fitness organization for which these formulas were once likely utilized in a training handbook. The origin of the eTBF index can be traced to the research of Wilmore and Behnke who used anthropometric measurements from multiple body sites to estimate body composition variables from regression equations among healthy college student volunteers \[[@CR13], [@CR14]\]. eTBF is relatively simple to calculate and is one of many anthropometry-based estimated body fat formulas currently in use. Our finding that eTBF was strongly correlated with total body fat by DXA, but not significantly associated with VAT by MRI (despite incorporation of WC as a derivation variable), supports its use as a surrogate for total body fat, but not abdominal adiposity, in the absence of DXA imaging. Whether eTBF is a better predictor of total body fat compared with other methods of body fat quantification remains to be seen.

WC has traditionally been considered one of the most valid indices of regional adipose tissue distribution with excellent correlation with VAT by abdominal imaging (correlation coefficient = 0.77 among 151 metabolically healthy men and women) \[[@CR17]\]. It also has a strong association with cardiovascular disease risk and mortality \[[@CR18]\]. As a result, the American Heart Association/National Heart, Lung, and Blood Institute has incorporated WC as a surrogate marker of abdominal/central obesity in their diagnostic definition of the metabolic syndrome \[[@CR19]\]. ICO, the index of WC to height, has also been extensively studied and may be superior to WC in predicting multiple cardiovascular risk factors in both sexes and different ethnic groups \[[@CR20]\]. However, WC is limited as a surrogate for the VAT phenotype. First, the correlation between WC and VAT is highly variable among different racial groups, prompting the International Diabetes Federation to define different cutoffs for abnormal WC in Asian populations \[[@CR21]\]. Nevertheless, we still observed a strong correlation between WC and VAT in our population with a significant proportion of Asian patients. Second, WC measurement includes both VAT and abdominal SAT compartments. These two depots are anatomically and physiologically distinct, especially within the obese population, and are differentially associated with markers of cardiometabolic risk \[[@CR3]\]. Nevertheless, our findings demonstrate strong correlations between WC and ICO and VAT among an ethnically diverse population with T2D, supporting their use when direct imaging assessments are not available.

VAI is a mathematical model-derived index based on both anthropometric and laboratory-based correlates of excess adiposity. It has been shown to positively associate with peripheral glucose utilization during euglycemic hyperinsulinemic clamp and (expectedly given its derivation) is correlated with cardiovascular risk \[[@CR15]\]. However, we found that the correlation between VAI and VAT as assessed by MRI was negligible, suggesting it does not sufficiently reflect the anatomic burden of VAT to warrant its use as a surrogate for clinical or research purposes. Further research should confirm these findings in varying populations with different demographic and clinical phenotypes.

Several study limitations merit comment. First, we are unable to report on the association of waist-hip ratio with direct imaging phenotypes as hip circumference was not measured in our study. Second, subgroup analyses by sex and age were not performed due to a limited sample size and the concern that multiple subgroup analyses on a limited patient sample may substantially increase the probability of false-positive findings \[[@CR22]\]. Further research should focus on validating these indices within larger, more diverse populations, including age- and sex-specific analyses given their strong influence on adipose distribution.

Conclusions {#Sec6}
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In conclusion, using baseline data from the EMPA-REG H2H SU trial, we found strong correlations between the adipose distribution indices of eTBF (YMCA formula) and total body fat by DXA and between WC and ICO and abdominal VAT and SAT by MRI. These findings support their use as surrogate measurements for clinical and research purposes in the absence of gold standard direct imaging assessments of body fat composition. Analyses of the recently reported EMPA-REG OUTCOME™ trial (NCT01131676) \[[@CR23]\] demonstrating decreased cardiovascular mortality of EMPA compared with placebo in a high-cardiovascular risk patient population may establish whether changes in such indices after EMPA treatment are associated with improved clinical outcomes.
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